

QUARTERLY INVESTOR CALL

Investor call at 9.00am AEDT, Thursday 29 February 2024

Adelaide, Australia, 26 February 2024: Australian medical technology company LBT Innovations Limited (ASX: LBT) (LBT or the Company), a leader in microbiology automation using artificial intelligence, is pleased to announce that the Company will hold an investor conference call at 9.00am AEDT on Thursday 29 February 2024 to discuss the Company's activities and financial results for the quarter ended 31 December 2023. The Conference Call will include an overview of the Company's recent commercial progress in the biopharmaceutical market and the business outlook. The Company's CEO and Managing Director, Brent Barnes, will host the call.

All attendees must register to attend the call. Please register using the link below. After registering, you will receive a confirmation email about joining the webinar including options to attend via computer or telephone.

https://us06web.zoom.us/webinar/register/WN N4dzbiakRg6EoTGGPzALvQ

A Q&A session will be held at the end of the conference call, to participate in this, you will need to join the conference via a computer. A recording of the call will be available on the Investor Centre section of the Company's website for 60 days after the call.

Approved for release by the Chair of the LBT Board.

- ENDS -

About LBT Innovations

LBT Innovations (LBT) provides intelligent automation solutions to microbiology laboratories. Based in Adelaide, South Australia, the Company has developed a best-in-class technology, the Automated Plate Assessment System (APAS® Independence), using artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading and is being commercialised through LBT's wholly owned subsidiary Clever Culture Systems AG (CCS). The product is currently being sold to microbiology laboratories in the pharmaceutical manufacturing sector for the reading of environmental monitoring culture plates and to clinical laboratories as an in vitro diagnostic for infectious diseases. Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence to clinical customers in the United States and selected countries in Europe.

INVESTOR ENQUIRIES

LBT Innovations

Brent Barnes

Chief Executive Officer & Managing Director

Tel: +61 8 8227 1555 E: info@lbtinnovations.com